Determining the Optimal Position for Vedolizumab in the Current Treatment Paradigm for Ulcerative Colitis: A Markov Model

被引：0
|
作者：
Scott, Frank I.
Shah, Yash
Lasch, Karen
Luo, Michelle
Lewis, James
机构：
来源：
GASTROENTEROLOGY | 2016年 / 150卷 / 04期
关键词：
D O I：
10.1016/S0016-5085(16)30457-7
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
511
引用
收藏
页码：S104 / S104
页数：1
相关论文
共 50 条
  • [1] Determining the Optimal Position For Vedolizumab In The Current Treatment Paradigm For Ulcerative Colitis: A Markov Model
    Scott, Frank I.
    Shah, Yash
    Lasch, Karen
    Luo, Michelle
    Lewis, James D.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 516 - 517
  • [2] Assessing the Optimal Position for Vedolizumab in the Treatment of Ulcerative Colitis: A Simulation Model
    Scott, Frank I.
    Shah, Yash
    Lasch, Karen
    Luo, Michelle
    Lewis, James D.
    [J]. INFLAMMATORY BOWEL DISEASES, 2018, 24 (02) : 286 - 295
  • [3] Evaluation of the Optimal Position for Vedolizumab in the Japanese Treatment Paradigm for Ulcerative Colitis Using Markov Modeling (vol 360, otaa017, 2020)
    Uda, Akihito
    Eto, Yuki
    Li, Yuxin
    Matsuda, Hiroyuki
    Demiya, Sven
    Watanabe, Tomoyuki
    Ota, Mihoko
    Iwakiri, Ryuichi
    Igarashi, Ataru
    [J]. CROHNS & COLITIS 360, 2020, 2 (02)
  • [4] Current position on Vedolizumab for ulcerative colitis and Crohn's disease
    Schreiber, S.
    Dignass, A. U.
    Hartmann, H.
    Kruis, W.
    Rogler, G.
    Siegmund, B.
    Stallmach, A.
    Witte, C.
    Bokemeyer, B.
    [J]. ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2015, 53 (06): : 591 - 602
  • [5] OPTIMAL POSITIONING OF COLECTOMY IN THE TREATMENT OF ULCERATIVE COLITIS: A MARKOV MODEL
    Chu, Brandon
    Scott, Frank I.
    Bewtra, Meenakshi
    [J]. GASTROENTEROLOGY, 2018, 154 (06) : S798 - S798
  • [6] WHAT IS THE MOST COST-EFFECTIVE POSITION OF VEDOLIZUMAB IN THE CURRENT TREATMENT ALGORITHM OF ULCERATIVE COLITIS?
    Scott, Frank I.
    Shah, Yash
    Lewis, James D.
    [J]. INFLAMMATORY BOWEL DISEASES, 2018, 24 : S46 - S46
  • [7] Vedolizumab for the treatment of ulcerative colitis
    Stallmach, Andreas
    Schmidt, Carsten
    Teich, Niels
    [J]. EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2016, 10 (02) : 165 - 175
  • [8] WHAT IS THE MOST COST-EFFECTIVE POSITION OF VEDOLIZUMAB IN THE CURRENT TREATMENT ALGORITHM OF ULCERATIVE COLITIS?
    Scott, Frank I.
    Shah, Yash
    Lewis, James D.
    [J]. GASTROENTEROLOGY, 2018, 154 (01) : S66 - S67
  • [9] Vedolizumab for the treatment of ulcerative colitis
    Shahidi, Neal
    Bressler, Brian
    Panaccione, Remo
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2016, 16 (01) : 129 - 135
  • [10] Vedolizumab for the treatment of ulcerative colitis
    Rietdijk, Svend T.
    D'Haens, Geert R.
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2014, 7 (04) : 423 - 430
12345